Navigation Links
Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
Date:9/14/2010

g, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development. Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). Optimer has completed two Phase 3 trials of fidaxomicin for the treatment of CDI demonstrating that fidaxomicin was statistically superior to vancomycin in global cure rate (defined as cure with no recurrence within four weeks of completing therapy) as well as statistically superior in reducing recurrences of CDI by up to 50% when compared with vancomycin, the only FDA approved product for CDI. Optimer has also successfully completed two Phase 3 trials of Pruvel™ a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Forward-looking Statements Statements included in this press release that are not a description of historical facts are forward-looking statements, including without limitation all statements related to the ability of fidaxomicin to treat CDI and address current treatment limitations, expectations regarding regulatory filings and the potential to bring fidaxomicin to the market. Words such as "believes," "anticipates," "plans," "expects," "intend," "will," "goal" and similar expressions are intended to identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Optimer that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Optimer's business including, without limitation, risks relating to: the timing, progress and likelihood of success of its product research a
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
2. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
3. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
4. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
5. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
6. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
7. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
8. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
9. Edimer Pharmaceuticals and CMC Biologics Announce Agreement to Manufacture EDI200 Recombinant Protein
10. Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference
11. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... The 20 ambassadors representing the ALS Therapy ... the following statement on Facebook today regarding the global ... funding specifically for ALS research: , “Who would have ... would raise all this awareness and funding toward ALS ... behalf of the entire ALS community, would like to ...
(Date:8/26/2014)... LONDON , Aug. 26, 2014 An ... gene structures of all Dengue virus strains in Pubmed, ... structures back to 1944. This conservation and sharing of ... a Synthetic Dengue Blocker-Vaccine™ candidate, as it did for ... vaccine, both of which have been found to be ...
(Date:8/26/2014)... 2014 The global market for molecular ... 2020, according to a new study by Grand View ... and the subsequent introduction of advanced cancer diagnostic technologies ... over the next six years. Moreover, the growing global ... cancer, coupled with disease triggering lifestyle habits such as ...
(Date:8/26/2014)... , Aug. 26, 2014   Loveland Products, a ... of high-performance crop input products and proprietary products ... the company has acquired a controlling interest in ... biotechnology company delivering biochemical-based products for efficient and ... Products, fastest growing plant nutrition brands, Accomplish ® ...
Breaking Biology Technology:ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 2ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 3ALS TDI’s Young Faces of ALS Ambassadors Thank You for Accepting the Ice Bucket Challenge to End ALS 4World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 2World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 3World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 4World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 5World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 6Agrium, through Loveland Products, Acquires a Controlling Interest in Agricultural Biotechnology Company Agricen 2Agrium, through Loveland Products, Acquires a Controlling Interest in Agricultural Biotechnology Company Agricen 3Agrium, through Loveland Products, Acquires a Controlling Interest in Agricultural Biotechnology Company Agricen 4
... NEW YORK, April 7 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals,Inc. ("Biostar" or the "Company") ... December 31, 2008. , , Highlights for Year Ended ... year were $33.9 million, up from $15.9 million, ... year increased 69% to $6,690,542 as compared to, ...
... ( http://www.volersystems.com ) has launched a "Quality System for ... concept and design to production of devices for human ... from investing in key programs that are critical to ... medical devices. During the economic recovery to come, Voler ...
... CARMEL, Israel, April 7 InSightec Ltd. announced,today that ... label,change for the company,s ExAblate(R) 2000 MR-guided Focused Ultrasound,(MRgFUS) ... fibroids. Under the new labeling, the agency allows,physicians to ... its previous,restriction to only treat up to half the ...
Cached Biology Technology:Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008 2Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008 3Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008 4Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008 5Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008 6Voler Systems Continues Investments and Expands Services 2FDA Approves Label Change for Non-Invasive Fibroid Treatment 2FDA Approves Label Change for Non-Invasive Fibroid Treatment 3
(Date:8/27/2014)... New York, NY (June, 2014) Outstanding basic ... treatments, and a dedication to patient care have ... of Columbia University Medical Center (CUMC) and NewYork-Presbyterian ... Grant from the National Cancer Institute (NCI). The ... only two NCI-designated Comprehensive Cancer Centers in New ...
(Date:8/27/2014)... that piglets can be weaned later with no negative ... the study at the University,s Roseworthy campus, published in ... important finding for pig producers. It allows improvements in ... "Sows don,t usually start their oestrous cycles again during ... been weaned," says Ms Alice Weaver, PhD candidate with ...
(Date:8/26/2014)... Researchers at Washington University in St. Louis have developed ... bones prone to tearing or breaking. The technology, which ... patients, one day may help pinpoint minor strains and ... problems occur. , The research is available online Aug. ... Interface , which publishes research at the nexus of ...
Breaking Biology News(10 mins):Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4Piglet weaning age no bar to litter frequency 2New technology may identify tiny strains in body tissues before injuries occur 2New technology may identify tiny strains in body tissues before injuries occur 3
... at the edge of Alaska,s tundra are growing faster, suggesting ... rapidly warming climate, says a new study. While forests ... attributed to global warming, some white spruce trees in the ... last hundred years, especially since 1950, the study has found. ...
... bike path in Montana to a backwater underneath a ... June to capture high-resolution images for the first Nearby ... in their efforts to document global biodiversity as they ... week of Dec. 19-26., The GigaBlitz is organized ...
... University of Sheffield comparing rats and mice with their ... an important milestone in the evolution of mammals from ... tracking, the research team, which was led by Professor ... shed light on how rodents such as mice and ...
Cached Biology News:Trees on tundra's border are growing faster in a hotter climate 2Trees on tundra's border are growing faster in a hotter climate 3Trees on tundra's border are growing faster in a hotter climate 4GigaBlitz event seeks citizen scientists to capture images of nearby biodiversity 2GigaBlitz event seeks citizen scientists to capture images of nearby biodiversity 3Whiskers marked milestone in evolution of mammals from reptiles 2
... pH 9 (x 10) This product ... for heat-induced target retrieval prior to immunohistochemical ... on formalin-fixed, paraffin-embedded tissue sections mounted on ... buffer, pH 6, the use of Target ...
... to off-white solid. Increases the expression of glutathione ... in H 2 O. Unstable in aqueous ... EK7713840, CAS 3211-76-5, M.W. 196.1. References: ... and Junod, A.F. 1995. Biochem. J. ...
... antifade reagent is used to ... standard fluorescence microscopy. The unique ... a wide variety of fixed ... fluorescein, rhodamine, sulforhodamine 101, coumarin, ...
...
Biology Products: